PROactive Study: PROspective pioglitAzone Clinical Trial In macroVascular Events

Abstract

Keywords

pioglitazone type 2 diabetes mellitus macrovascular events.

Get full access to this article

View all access options for this article.

References

Campbell IW

Pioglitazone - an oral antidiabetic agent and metabolic syndrome modulator. Can therapy translate into practice?

Br J Diabetes Vasc Dis 2005;5:209-16.

McCallum RW , Fisher M. From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes . Br J Diabetes Vasc Dis 2005;5:218-25.

Charbonnel B. , Dormandy J. , Erdmann E. , Massi-Benedetti M. , Skene A. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004;27:1647-53.

Staels B. PPARγ and atherosclerosis. Curr Med Res Opin 2005;21(suppl 1):S13-S20.

Goldberg RB , Kendall DM , Deeg MA et al. A comparison of lipid and glycaemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidaemia. Diabetes Care 2005;28:1547-54.

Bertoni AG , Hundley WG , Massing MW et al. Heart failure prevalence, incidence and mortality in the elderly with diabetes. Diabetes Care 2004;27:699-703.

Belcher G. , Lambert C. , Goh KL et al. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J CLin Pract 2004;58:833-7.

Karter AJ , Ahmed AT , Liu J. , Moffet HH , Parker MM Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005;22:986-93.